IP Library › Granted Patent US 12,742,015
Granted Patent B2
US 12,742,015 · App. 19/283,716 · Granted Sep 22, 2026

Affinity matured anti-OX40 antibodies and use thereof

Inventors: Julie Macoin (La Chaux-de-Fonds, CH); Thierry Monney (La Chaux-de-Fonds, CH); Nikolaos Biris (Westborough, MA); Jill C. Milne (Boston, MA); Christopher J. Morabito (Lexington, MA); Chunxia Zhao (Boston, MA)
Assignees: Ichnos Sciences SA; Astria Therapeutics, Inc.
C07K16/2878C07K2317/33C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,742,015
App. No.
19/283,716
Granted
Sep 22, 2026
Kind
B2
Abstract

Provided herein are high affinity antagonistic anti-OX40 antibodies, methods of making such antibodies, and methods of using such antibodies to treat OX40-mediated disorders.

Claims (45)

1 . An antibody, or antigen binding fragment thereof, that binds to OX40 comprising:

a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:3; and

b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:38 or 71, where X 1 is F, T, W, or M; where X 2 is G, I, V, L, or E; where X 3 is A, D, E, L, H, T, or F; and where X 4 is W, P, F, Y, or T.

2 . The antibody, or antigen binding fragment thereof, of claim 1 , wherein the CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO:38.

3 . The antibody, or antigen binding fragment thereof, of claim 1 , wherein X 1 is F, X 2 is G, X 3 is A, and X 4 is W or CDR-L3 comprises the amino acid sequence of SEQ ID NO:6.

4 . The antibody, or antigen binding fragment thereof, of claim 1 , wherein CDR-L3 comprises the amino acid sequence of SEQ ID NO:11, 14, 17, 20, 23, 26, or 29.

5 . The antibody or antigen binding fragment thereof that binds to OX40 of claim 1 , wherein the antibody is selected from:

a) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and, CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:8;

b) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:12;

c) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:15

d) an antibody comprising three heavy chain complementarity determining regions (DR s) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:18;

e) an antibody comprising three heavy chain complementarity determining regions (DR s) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:21;

f) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:24;

g) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:27; or

h) an antibody comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:30.

6 . The antibody or antigen binding fragment thereof that binds to OX40 of claim 5 , comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:7 and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), of a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:8.

7 . The antibody or antigen binding fragment of claim 5 , wherein:

a) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Kabat;

b) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Chothia;

c) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to IMGT;

d) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to AbM;

e) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Contact; or

f) the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Honneger (AHo).

8 . The antibody or antigen binding fragment thereof of claim 5 , wherein:

the heavy chain CDR-H1 comprises the amino acid sequence of SEQ ID NO:1, the heavy chain CDR-H2 comprises the amino acid sequence of SEQ ID NO:2, the heavy chain CDR-H3 comprises the amino acid sequence of SEQ ID NO:3, the light chain CDR-L1 comprises the amino acid sequence of SEQ ID NO:4, the light chain CDR-L2 comprises the amino acid sequence of SEQ ID NO:5, and the light chain CDR-L3 comprise the amino acid sequence of SEQ ID NO:6.

9 . The antibody or antigen binding fragment thereof of claim 5 , wherein the antibody or antibody or antigen binding fragment thereof comprises:

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:8; or

(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence selected from SEQ ID NO:12, 15, 18, 21, 24, 27, or 30.

10 . The antibody or antigen binding fragment thereof of claim 5 , wherein the antibody or antigen binding fragment thereof comprises:

(a) a heavy chain Fc region comprising an amino acid modification that increases the serum half-life of the antibody or antigen binding fragment thereof;

(b) an IgG1 heavy chain; or

(c) an IgG1 heavy chain Fc region comprising the mutations M252Y, S254T, and T256E as numbered according to EU numbering.

11 . The antibody or antigen binding fragment thereof of claim 5 , wherein the antibody or antigen binding fragment thereof comprises:

(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10, 13, 16, 19, 22, 25, 28, or 31;

(b) a heavy chain comprising the amino acid sequence of SEQ ID NO:73 and a light chain comprising the amino acid sequence of SEQ ID NO:13, 16, 19, 22, 25, 28, or 31; or

(c) a heavy chain comprising the amino acid sequence of SEQ ID NO:73 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

12 . An isolated nucleic acid comprising a nucleotide sequence encoding the heavy chain complementarity determining regions and the light chain complementarity determining regions of the antibody or antigen binding fragment thereof of claim 5 .

13 . An expression vector comprising the nucleic acid of claim 12 .

14 . A host cell comprising the expression vector of claim 13 .

15 . A method of producing an antibody, or antigen binding fragment thereof, that binds to human OX40, the method comprising:

(a) growing the host cell of claim 14 under conditions so that the host cell expresses a polypeptide or polypeptides comprising the heavy chain or heavy chain variable region and a polypeptide or polypeptides comprising the light chain or light chain variable region, thereby producing the antibody or the antigen-binding fragment of the antibody; and

(b) purifying the antibody or the antigen-binding fragment of the antibody.

16 . A pharmaceutical composition comprising the antibody or antigen binding fragment of claim 5 , and a pharmaceutically acceptable carrier.

17 . The antibody or antigen binding fragment thereof of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

18 . The antibody or antigen binding fragment thereof of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:73 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2025
From: BIRIS, NIKOLAOS; MILNE, JILL C.; MORABITO, CHRISTOPHER J.; ZHAO, CHUNXIA
To: ASTRIA THERAPEUTICS, INC.
Reel/Frame 071922/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2025
From: MACOIN, JULIE
To: ICHNOS SCIENCES SA
Reel/Frame 071923/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2025
From: MONNEY, THIERRY
To: ICHNOS SCIENCES SA
Reel/Frame 071923/0174 →
Continuity (4)
Continuation PCTUS2024050127 · Oct 4, 2024
Provisional Application 63645656 · May 10, 2024
Provisional Application 63588662 · Oct 6, 2023
Related Publication 20250353921A1 · Nov 20, 2025
References Cited (136)
US 6875433B2 · Hart et al. · 2005 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7531170B1 · Croft et al. · 2009 [cited by applicant]
US 7605237B2 · Stevens et al. · 2009 [cited by applicant]
US 7635167B2 · Okazaki · 2009 [cited by applicant]
US 7670600B2 · Dall'Acqua et al. · 2010 [cited by applicant]
US 7722876B2 · Polonelli et al. · 2010 [cited by applicant]
US 7807156B1 · Croft et al. · 2010 [cited by applicant]
US 7928074B2 · Khare · 2011 [cited by applicant]
US 8110664B2 · Sanders et al. · 2012 [cited by applicant]
US 8283450B2 · Kato et al. · 2012 [cited by applicant]
US 8614295B2 · Lawson et al. · 2013 [cited by applicant]
US 8748585B2 · Attinger et al. · 2014 [cited by applicant]
US 8956615B1 · Croft et al. · 2015 [cited by applicant]
US 8962807B2 · Verdonck et al. · 2015 [cited by applicant]
US 9040048B2 · Adams et al. · 2015 [cited by applicant]
US 9139653B1 · Campbell et al. · 2015 [cited by applicant]
US 9200060B2 · Kannan et al. · 2015 [cited by applicant]
US 9428570B2 · Lawson et al. · 2016 [cited by applicant]
US 9475848B2 · Dehottay et al. · 2016 [cited by applicant]
US 9493563B2 · Blein et al. · 2016 [cited by applicant]
US 9803023B2 · Chamberlain et al. · 2017 [cited by applicant]
US 9834611B2 · Verdonck et al. · 2017 [cited by applicant]
US 9873735B2 · Adams et al. · 2018 [cited by applicant]
US 9969810B2 · Kato et al. · 2018 [cited by applicant]
US 10017575B2 · Lawson et al. · 2018 [cited by applicant]
US 10106619B2 · Croft et al. · 2018 [cited by applicant]
US 10822425B2 · Verdonck et al. · 2020 [cited by applicant]
US 11117972B2 · Eckelman et al. · 2021 [cited by applicant]
US 11192953B2 · Kato et al. · 2021 [cited by applicant]
US 11407839B2 · Attinger et al. · 2022 [cited by applicant]
US 11779604B2 · Bland-Ward et al. · 2023 [cited by applicant]
US 12281169B2 · Attinger et al. · 2025 [cited by applicant]
US 20090041770A1 · Chamberlain et al. · 2009 [cited by applicant]
US 20160355597A1 · Rhee et al. · 2016 [cited by applicant]
US 20210206864A1 · Back et al. · 2021 [cited by applicant]
US 20210214453A1 · Back et al. · 2021 [cited by applicant]
US 20220251138A1 · Giovannini et al. · 2022 [cited by applicant]
US 20220273796A1 · Dubey et al. · 2022 [cited by applicant]
US 20250051468A1 · Qiu et al. · 2025 [cited by applicant]
EP 4450522A2 · 2024 [cited by applicant]
WO WO2007062245A2 · 2007 [cited by applicant]
WO WO2008106116A2 · 2008 [cited by applicant]
WO WO2010096418A2 · 2010 [cited by applicant]
WO WO2013008171A1 · 2013 [cited by applicant]
WO WO2013084157A1 · 2013 [cited by applicant]
WO WO2016022468A1 · 2016 [cited by applicant]
WO WO2016179517A1 · 2016 [cited by applicant]
WO WO2017096182A1 · 2017 [cited by applicant]
WO WO2017134292A1 · 2017 [cited by applicant]
WO WO2018089628A1 · 2018 [cited by applicant]
WO WO2018112346A1 · 2018 [cited by applicant]
WO WO2019038742A1 · 2019 [cited by applicant]
WO WO2019223733A1 · 2019 [cited by applicant]
WO WO2019229155A1 · 2019 [cited by applicant]
WO WO2020011759A1 · 2020 [cited by applicant]
WO WO2020016417A1 · 2020 [cited by applicant]
WO WO2021013372A1 · 2021 [cited by applicant]
WO WO2021013385A1 · 2021 [cited by applicant]
WO WO2022029447A1 · 2022 [cited by applicant]
WO WO2022075476A1 · 2022 [cited by applicant]
WO WO2022198055A1 · 2022 [cited by applicant]
WO WO2022250502A1 · 2022 [cited by applicant]
WO WO2023017252A1 · 2023 [cited by applicant]
WO WO2023061424A1 · 2023 [cited by applicant]
WO WO2023109976A2 · 2023 [cited by applicant]
WO WO2023152486A1 · 2023 [cited by applicant]
Genbank “HQ680975” accessed from uniprot.org on Dec. 8, 2025 (Year: 2011). [cited by examiner]
Kussie “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity” J immunol 152(1):146-52 (Year: 1994). [cited by examiner]
Reitz “Toward precision medicine in Alzheimer's disease” Ann transl med 4(6):107 (Year: 2016). [cited by examiner]
Stanford “Alzheimer's prevention, treatment and research—A Q and A with Dr Frank Longo” accessed from Stanfordhealthcare.org on May 3, 2016 (Year: 2016). [cited by examiner]
Phase 2b Study to Evaluate Efficacy and Safety of ISB 830 in Adults with Moderate to Severe Atopic Dermatitis, ClinicalTrials.gov ID NCT03568162, Sponsor: Ichnos Sciences, SA; Aug. 8, 2022 (77 pages). [cited by applicant]
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults with Moderate-to-Severe Atopic Dermatitis, ClinicalTrials.gov ID NCT02683928, Sponsor: Ichnos Sciences SA; May 18, 2020 (54 pages). [cited by applicant]
Akiba, H et al. “CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.” Journal of immunology (Baltimore, Md. : 1950) vol. 162, 12 (1999): 7058-66. [cited by applicant]
Astria Therapeutics, Inc. “Annual Report” (Form 10-K) filed with the U.S. Securities & Exchange Commission on Mar. 4, 2024 (302 pages). [cited by applicant]
Astria Therapeutics, Inc. “Prospecuts Supplement” (Form 424B-B5) filed with the U.S. Securities & Exchange Commission on Mar. 4, 2024 (46 pages). [cited by applicant]
Astria Therapeutics, Inc. “Quarterly Report” (Form 10-Q) filed with the U.S. Securities & Exchange Commission on Aug. 12, 2024 (48 pages). [cited by applicant]
Astria Therapeutics, Inc. “Quarterly Report” (Form 10-Q) filed with the U.S. Securities & Exchange Commission on May 9, 2024 (34 pages). [cited by applicant]
Astria Therapeutics, Inc. “Quarterly Report” (Form 10-Q) filed with the U.S. Securities & Exchange Commission on Nov. 13, 2023 (90 pages). [cited by applicant]
Astria Therapeutics, Inc. “Registration Statement” (Form S-3) filed with the U.S. Securities & Exchange Commission on Dec. 15, 2023 (78 pages). [cited by applicant]
Astria Therapeutics, Inc. Prospectus Supplement (Form 424-B5) filed with the U.S. Securities & Exchange Commission on Oct. 12, 2023 (65 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Aug. 2024,” published Aug. 12, 2024 (26 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Feb. 2024,” published Feb. 8, 2024, (29 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Jeffries London Nov. 2023,” published Nov. 15, 2023 (21 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Jun. 2024,” published Jun. 3, 2024, (27 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Mar. 2024”, published Mar. 4, 2024 (23 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation May 2024”, published May 9, 2024 (25 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Corporate Presentation Nov. 2023” published Nov. 13, 2023 (29 pages). [cited by applicant]
Astria Therapeutics, Inc., “Astria Therapeutics Oct. 2023,” published Oct. 12, 2023 (28 pages). [cited by applicant]
Astria Therapeutics, Inc., “Corporate Presentation Dec. 2024,” published Dec. 11, 2024 (28 pages). [cited by applicant]
Astria Therapeutics, Inc., “STAR-0310,” accessed at https://astriatx.com/our-science/star-0310 on Aug. 21, 2024 (3 pages). [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Announces Exclusive Worldwide Licensed Agreement with Ichnos Sciences for OX40 Portfolio,” dated Oct. 11, 2023 (2 pages). [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, A monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis,” dated Dec. … [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update,” dated May 9, 2024 (4 pages). [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Reports Fourth Quarter and Full 2023 Financial Results and Provides a Corporate Update,” dated Mar. 4, 2024 (4 pages). [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update,” dated Aug. 12, 2024 (4 pages). [cited by applicant]
Astria Therapeutics, Inc., Press Release entitled “Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update,” dated Nov. 13, 2023 (4 pages). [cited by applicant]
Biris et al., “Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody”—Abstract—European Academy of Allergy and Clinical Immunology (EAACI) Congress, May 31-Jun. 1, 2024, Valencia, … [cited by applicant]
Biris et al., “Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody”—Poster presented at European Academy of Allergy and Clinical Immunology (EAACI) Congress, Jun. 1, 2024, Valenc… [cited by applicant]
Blauvelt, Andrew et al. “Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty Ad Chronos): a 1-year, randomised, double-blinded, placebo-controlled… [cited by applicant]
Booth, Brian J et al. “Extending human IgG half-life using structure-guided design.” mAbs vol. 10,7 (2018): 1098-1110. doi:10.1080/19420862.2018.1490119. [cited by applicant]
Calderhead, D M et al. “Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.” Journal of immunology (Baltimore, Md. : 1950) vol. 151, 10 (1993): 5261-71. [cited by applicant]
Croft, Michael et al. “OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target.” American journal of clinical dermatology vol. 25,3 (2024): 447-461. doi:10.1007/s40257-023-00838-9. [cited by applicant]
Croft, Michael et al. “The significance of OX40 and OX40L to T-cell biology and immune disease.” Immunological reviews vol. 229,1 (2009): 173-91. doi:10.1111/j.1600-065X.2009.00766.x. [cited by applicant]
Dall'Acqua, William F et al. “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.” Journal of immunology (Baltimore, Md. : 1950) vol. 169,9 (2002): 5171-80. doi:10.4049/jimmuno… [cited by applicant]
Dall'Acqua, William F et al. “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).” The Journal of biological chemistry vol. 281,33 (2006): 23514-24. doi:10.1074/jbc.M604292200. [cited by applicant]
Facheris, Paola et al. “The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.” Cellular & molecular immunology vol. 20,5 (2023): 448-474. doi:10.1038/s41423-023-00992-4. [cited by applicant]
Gramaglia, I et al. “Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.” Journal of immunology (Baltimore, Md. : 1950) vol. 161,12 (1998): 6510-7. [cited by applicant]
Griffin, M Pamela et al. “Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.” Antimicrobial a… [cited by applicant]
Guttman-Yassky, Emma et al. “An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.” Lancet (London, England) vol. 401,10372 (2023): 204-214.… [cited by applicant]
Guttman-Yassky, Emma et al. “GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.” The Journal of allergy and clinical immunology vol. 144,2 (2019): 482-493.e7. do… [cited by applicant]
International Search Report for International Patent Application No. PCT/US2024/050127 by Ichnos Sciences SA mailed Dec. 23, 2024, from the International Searching Authority/Australian Patent Office (7 pages). [cited by applicant]
Kondělková, Katerina et al. “Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders.” Acta medica (Hradec Kralove) vol. 53,2 (2010): 73-7. doi:10.14712/18059694.2016.63. [cited by applicant]
Lé, Ana Maria, and Tiago Torres. “OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.” Pharmaceutics vol. 14, 12 2753. Dec. 8, 2022, doi:10.3390/pharmaceutics14122753. [cited by applicant]
Lobefaro, Fabio et al. “Atopic Dermatitis: Clinical Aspects and Unmet Needs.” Biomedicines vol. 10,11 2927. Nov. 14, 2022, doi:10.3390/biomedicines10112927. [cited by applicant]
Miyano, Takuya et al. “A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis.” Allergy vol. 77,2 (2022): 582-594. doi:10.1111/all. 14870. [cited by applicant]
Ohshima, Y et al. “OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors.” Blood vol. 92,9 (1998): 3338-… [cited by applicant]
Picone, Vincenzo et al. “An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.” Expert review of clinical pharmacology vol. 16, 12 (2023): 1239-1248. doi:10.1080/17512433.20… [cited by applicant]
Ralph, Kerry et al., “Identification and characterization of an antagonistic anti-mouse CD40 antibody.” The Journal of Immunology, vol. 196, Issue 1 Supplement, May 2016, p. 70.19, https://doi.org/10.4049/jimmunol.196.S… [cited by applicant]
Ratchataswan, Thanaporn et al. “Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.” The journal of allergy and clinical immunology. In practice vol. 9,3 (2021): 1053-1065. doi:10.1016/j.ja… [cited by applicant]
Renert-Yuval, Yael, and Emma Guttman-Yassky. “What's New in Atopic Dermatitis.” Dermatologic clinics vol. 37,2 (2019): 205-213. doi:10.1016/j.det.2018.12.007. [cited by applicant]
Rewerska, Barbara et al. “Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate- to-severe atopic dermatitis.” The journal of allergy and clinical immunology. Global vol. 3,1 100195. Nov. 22, 2023, doi:1… [cited by applicant]
Sadrolashrafi, Kaviyon et al. “An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis.” Cells vol. 13,7 587. Mar. 28, 2024, doi:10.3390/cells13070587. [cited by applicant]
Silverberg, Jonathan I. “Comorbidities and the impact of atopic dermatitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology vol. 123,2 (2019): 144-… [cited by applicant]
Sroka-Tomaszewska, Jowita, and Magdalena Trzeciak. “Molecular Mechanisms of Atopic Dermatitis Pathogenesis.” International journal of molecular sciences vol. 22,8 4130. Apr. 16, 2021, doi:10.3390/ijms22084130. [cited by applicant]
Tidwell, W James, and Joseph F Fowler Jr. “T-cell inhibitors for atopic dermatitis.” Journal of the American Academy of Dermatology vol. 78,3 Suppl 1 (2018): S67-S70. doi:10.1016/j.jaad.2017.12.020. [cited by applicant]
Uppal, Shelley K et al. “Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis.” The Journal of dermatological treatment vol. 33,2 (2022): 626-636. doi:10.10… [cited by applicant]
Voo, Kui S et al. “Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.” Journal of immunology (Baltimore, Md. : 1950) vol. 191,7 (2013): 3641-50. doi:10.40… [cited by applicant]
Weidinger, Stephan et al. “Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase lla randomized placebo-controlled tr… [cited by applicant]
Written Opinion for International Patent Application No. PCT/US2024/050127 by Ichnos Sciences SA mailed Dec. 23, 2024, from the International Searching Authority/Australian Patent Office (6 pages). [cited by applicant]
Yang, Nan et al. “Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.” BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 35,4 (2021): 401-415. doi:10.1007/s40259-021-0… [cited by applicant]
Zahavi, David et al. “Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy.” Antibody therapeutics vol. 1,1 7-12. Jun. 24, 2018, doi:10.1093/abt/tby002. [cited by applicant]
Zhang, Di et al. “Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.” The Journal of biological chemistry vol. 291,53 (2016): 27134-27146. doi:10.1074/jbc.M116.757773. [cited by applicant]
Zhao et al., “Preclinical Profile of STAR-0310, a novel OX40 antagonistic monoclonal antibody”—Abstract 558, Journal of Investigative Dermatology, vol. 144, Issue 8, Supplement, S97, Aug. 2024 (Abstract initially publis… [cited by applicant]
Zhao et al., “Preclinical Profile of STAR-0310, a novel OX40 antagonistic monoclonal antibody”—Poster presented at Society for Investigative Dermatology on May 16, 2024, in Dallas, Texas, USA. [cited by applicant]
“Telazorlimab,” International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 84, WHO Drug Information, vol. 34, No. 3, 2020, p. 687, 776, 777. [cited by applicant]